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Background: T-wave alternans is useful for predicting the occurrence of ventricular tachyarrhythmias
and sudden cardiac death in various heart diseases. However, little is known about the clinical
signiﬁcance of T-wave alternans measurement in survivors of ventricular ﬁbrillation (VF) or hemody-
namically unstable ventricular tachycardia (VT).
Methods: We studied 28 patients with organic heart disease who survived VF or hemodynamically
unstable VT (20 males, mean age 63 years). Echocardiography, electrocardiogram (QRS duration and QTc
intervals), and Holter monitoring (heart rate variability, heart rate turbulence and T-wave alternans)
were performed before implantable cardioverter-deﬁbrillator (ICD) implantation. Positive T-wave
alternans was deﬁned as 465 μV. During the follow-up period (10.276.2 months), ventricular
tachyarrhythmias requiring appropriate shock therapy occurred in eight patients (29%). The subjects
were divided into two groups, based on whether appropriate shock therapy was required (n¼8, Group A)
or not (n¼20, Group B). Parameters from echocardiography, electrocardiogram, and Holter monitoring
were compared between the two groups in order to investigate their relationship with the incidence of
shock therapy after ICD implantation.
Results: The prevalence of positive T-wave alternans was signiﬁcantly higher in Group A than in Group B
(88% vs. 15%, P¼0.004). Univariate Cox proportional hazard analysis showed that, among the variables
measured, only T-wave alternans had predictive power for recurrent ventricular tachyarrhythmias
(hazard ratio, 13.17; 95% conﬁdence interval: 1.606–108.1, P¼0.016).
Conclusions: These results suggest that T-wave alternans by Holter monitoring is useful for predicting
recurrent ventricular tachyarrhythmias in survivors of VF or hemodynamically unstable VT.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Ventricular ﬁbrillation (VF) is the most common cause of
sudden cardiac death [1]. Survivors of VF require more careful
post-resuscitation care, because this arrhythmia is associated with
a high rate of recurrence and a poor prognosis after successful
resuscitation. Therefore, the implantable cardioverter-deﬁbrillator
(ICD) for the secondary prevention of VF has already become an
essential treatment to reduce the risk of sudden cardiac death and
improve survival [2–4]. On the other hand, it has been shown that
ICD shock therapy itself is linked with a deterioration in cardiac
function, and may lead to high cardiac mortality [5]. Thus, the
recurrence of ventricular tachyarrhythmias after ICD implantation
is a critical problem in patients who have previously experienced
lethal ventricular tachyarrhythmias. In order to improve patients'
survival after ICD implantation, an effective means of predicting
which of them are at high risk for sudden cardiac death is required
in the clinical setting.
Recently, T-wave alternans (TWA) has been shown to be useful
for predicting the prevalence of fatal ventricular tachyarrhythmias
and sudden cardiac death in various heart diseases [6–9]. TWA is
analyzed by the conventional power spectral method, using an
exercise stress protocol, or by the time-domain modiﬁed moving
average method, using Holter monitoring [10]. From the point of
view of risk assessment, TWA by the time-domain modiﬁed
moving average method has been demonstrated to be equivalent
to the conventional spectral method in the long-term prediction of
cardiac death [11]. However, the clinical signiﬁcance of TWA
measurement in survivors of VF or hemodynamically unstable
ventricular tachycardia (VT) has not been fully elucidated.
Therefore, using the time-domain modiﬁed moving average
method, we investigated the prognostic value of TWA as a predictor
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of recurrent ventricular tachyarrhythmias requiring shock therapy in
patients with organic heart disease who had survived VF or hemo-
dynamically unstable VT.
2. Material and methods
The study subjects were 28 consecutive patients with organic
heart disease who underwent ICD implantation for the secondary
prevention of sudden cardiac death, based on the indications for
ICD implantation in the European Society of Cardiology's guide-
lines [12]. The reason for ICD therapy in these patients was
previously documented VF or hemodynamically unstable VT
requiring electrical shock therapy. The exclusion criteria were
the presence of atrial ﬁbrillation, idiopathic VF (including Brugada
syndrome), and acute coronary syndrome. Ischemic patients had a
history of coronary intervention, including balloon angioplasty or
stenting, and they were in stable condition at enrollment.
An electrocardiogram was recorded (QRS duration and QTc
intervals) and Holter monitoring (heart rate variability, heart rate
turbulence, and TWA) was performed before ICD implantation. At
the same time, blood samples were taken for measurement of B-
type natriuretic peptide (BNP), left ventricular ejection fraction
(LVEF) was assessed using echocardiography, and New York Heart
Association functional class was determined based on the clinical
history. During the follow-up period (10.276.2 months), ventri-
cular tachyarrhythmias requiring appropriate shock therapy
occurred in eight patients (29%). The subjects were divided into
two groups based on whether appropriate shock therapy was
required (n¼8, Group A) or not (n¼20, Group B). Parameters from
echocardiography, electrocardiogram, and Holter monitoring
were compared between the two groups, in order to investigate
their relationship with the incidence of shock therapy after ICD
implantation.
Written informed consent was obtained from all study subjects.
The study protocol was approved by the ethical committee of
Fukushima Medical University (approval number: 1656, approval
date: 22 April, 2013).
2.1. Twelve-lead electrocardiogram analysis
We used a standard 12-lead electrocardiogram tracing at 25 mm/s
paper speed and 10mm/mV amplitude (FCP-7541, Fukuda Denshi,
Tokyo, Japan). QRS durations and heart rate were reported on the
electrocardiogram recording. The QT interval was measured manually
and corrected (QTc) using Bazett's formula [13].
2.2. Holter monitoring
In a manner similar to that used in routine Holter-based ST-
segment analysis, the greatest TWA magnitudes were examined
separately for each of the two leads (the bipolar modiﬁed V1 and
V5 leads). TWA voltage was analyzed by the time-domain modiﬁed
moving average method using a MARS PC Holter Monitoring and
Review System (version 7, GE Healthcare, Milwaukee, WI, USA).
The modiﬁed moving average method has been described in a
previous study by Nearing et al. [14]. In brief, the algorithm
continuously streams odd and even beats into separate bins and
creates average complexes for each bin. Average morphologies of
both the odd and even beats are continuously updated by a
weighting factor of one-eighth of the difference between the
ongoing average and the new incoming beats. TWA voltage is
calculated as the maximum difference in amplitude between the
odd and even median complexes from the J point to the end of the
T-wave for each 15 s beat stream. A TWA voltage 465 μV is useful
for predicting fatal ventricular arrhythmia in various heart dis-
eases [10].
In the present study, we deﬁned a positive TWA as 465 μV.
TWA voltages at heart rates 4120 beats/min or those with high
noise levels 420 μV were excluded from the analysis. Positive
TWA was analyzed in the modiﬁed V1 and V5 leads; of these two
leads, the one with the higher TWA voltage was termed the higher
lead. The maximum TWA voltage and the prevalence of positive
TWA were compared between the two groups.
In heart rate variability analysis, the standard deviation of all
R–R intervals and the standard deviation of the 5-min mean R–R
intervals were calculated by time-domain analysis. In this study, as
no recordings had 415% noise or ectopic beats during the 24-h
period, TWA and heart rate variability were measured in all
patients. Heart rate turbulence parameters included turbulence
onset and turbulence slope, which were determined according to a
previous study [15].
The total number of single ventricular premature complexes
was determined over a single day. In addition, the presence of
non-sustained VT, deﬁned as more than 3 repetitive ventricular
premature complexes with a heart rate 4100 beats/min, was
determined, since a previous study [16] reported that the presence
of non-sustained VT in Holter monitoring was an independent
marker for higher overall mortality and incidence of sudden death.
2.3. Long-term follow up
The study subjects were implanted with Medtronic devices
(Securas or Protectas; Medtronic Inc., Minneapolis, MN, USA) or
St. Jude Medical devices (Currents or Fortifys; St. Jude Medical, St.
Paul, MN, USA). These devices were dual-chamber ICDs. During the
follow-up period (10.276.2 months) after ICD implantation,
patients were followed-up according to a scheduled protocol, with
regular visits at 1, 3, and 6 months, and every 6 months thereafter.
Detected episodes were classiﬁed as ventricular tachyarrhythmias,
supraventricular tachyarrhythmias, or other events, according to
established criteria. We investigated the prevalence of fatal ven-
tricular tachyarrhythmias requiring appropriate shock therapy,
since a recent study has reported that the occurrence of at least
one appropriate ICD shock is associated with a poor prognosis [5].
2.4. Statistical analysis
Statistical analyses were performed using SPSS (version 17,
SPSS Inc., Chicago, IL, USA). Data are presented as mean7SD.
Differences between the two groups were assessed by the
unpaired Student t-test for continuous variables, and categorical
variables were assessed by Fisher's exact test. A value of Po0.05
was considered statistically signiﬁcant. Univariate Cox propor-
tional hazard analysis was used to investigate the association
between covariates and the prevalence of ventricular tachyar-
rhythmias requiring appropriate shock therapy. Receiver-
operating characteristic (ROC) analysis for the identiﬁcation of
ventricular tachyarrhythmias was performed to calculate the
sensitivity, speciﬁcity, areas under the ROC curve, and the optimal
cutoff value. The event-free survival of patients with ventricular
tachyarrhythmias was evaluated by the Kaplan–Meier method and
analyzed using a log-rank test.
3. Results
3.1. Clinical characteristics of study subjects
Table 1 shows the baseline clinical characteristics of the study
subjects. The study population consisted of 28 patients (71% men,
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mean age 63.7715.8 years) who had previously documented VF
(71%) or hemodynamically unstable VT (29%) that required elec-
trical shock therapy. The patients had either ischemic heart
disease (n¼13), or non-ischemic heart disease (n¼15) including
dilated cardiomyopathy (n¼10), hypertensive heart disease (n¼3),
and valvular heart disease (n¼2). Cardiac function judged from
BNP levels (mean 176.6 pg/mL) or LVEF (mean 46.3%) indicated
mild depression. Most patients were receiving optimal medical
therapy, as evidenced by the 68%, 71%, and 39% usage rates for β
blockers, angiotensin-converting enzyme inhibitors, and/or angio-
tensin II receptor blockers and amiodarone, respectively.
3.2. Ventricular tachyarrhythmias requiring shock therapy during
follow up
During the follow-up period (10.276.2 months), 8 (29%)
patients had ventricular tachyarrhythmias requiring appropriate
shock therapy. Among these 8 patients, 3 (38%) patients died of
cardiac causes, despite frequent treatment modiﬁcations, and 3
(38%) patients underwent radiofrequency ablation for the recur-
rence of ventricular tachyarrhythmias, despite drug treatment
modiﬁcations and the optimization of antiarrhythmic ICD inter-
vention protocols.
3.3. Comparison of patients with or without recurrent ventricular
tachyarrhythmias
As shown in Table 2, the prevalence of positive TWA and the
maximum TWA voltage was signiﬁcantly higher in Group A than in
Group B (positive TWA: 88% vs. 15%, P¼0.004; maximum TWA
voltage: 79.8721.7 μV vs. 58.6719.1 μV, P¼0.018). In addition,
the use of β blockers was signiﬁcantly higher in Group A than in
Group B (100% vs. 55%, P¼0.029). Other parameters did not differ
between the two groups.
We next investigated the relationship between the covariates
and incidence of shock therapy (Table 3). Univariate Cox propor-
tional hazard analysis showed that the prevalence of positive TWA
and the maximum TWA voltage had predictive power for the
recurrence of ventricular tachyarrhythmias requiring shock ther-
apy (positive TWA: hazard ratio [HR] 13.17, 95% conﬁdence interval
[CI]: 1.606–108.1, P¼0.016; maximum TWA voltage: HR 1.026, 95%
CI: 1.003–1.049, P¼0.028).
3.4. Cutoff values of T-wave alternans for predicting recurrent
ventricular tachyarrhythmias
The best operating TWA cutoff value determined by ROC
analysis for predicting the recurrence of ventricular tachyarrhyth-
mias was 70.5 μV. Comparisons of TWA values between Group A
and Group B are shown in Fig. 1. High TWA values (Z70.5 μV)
were found in 7 (87.5%) patients of Group A and 2 (10.0%) of
Group B. The area under the ROC curve for predicting recurrent
ventricular tachyarrhythmias was 0.816 (Fig. 2). The sensitivity and
Table 1
Clinical characteristics (n¼28).
Age (years) 63.7715.8
Male (n, %) 20 (71%)
Etiology
Ischemic heart disease (n, %) 13 (46%)
Dilated cardiomyopathy (n, %) 10 (36%)
Hypertensive heart disease (n, %) 3 (11%)
Valvular heart disease (n, %) 2 (7%)
BNP (pg/mL) 176.67177.8
LVEF (%) 46.3714.1
NYHA functional class 2.070.5
Medication
β Blockers (n, %) 19 (68%)
ACE-inhibitors/ARBs (n, %) 20 (71%)
Amiodarone (n, %) 11 (39%)
Reason for ICD implantation
VF (n, %) 20 (71%)
Hemodynamically unstable VT (n, %) 8 (29%)
BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association; ACE-inhibitors, angiotensin-converting enzyme inhibitors;
ARBs, angiotensin II receptor blockers; ICD, implantable cardioverter-deﬁbrillator;
VF, ventricular ﬁbrillation; and VT, ventricular tachycardia.
Table 2
Clinical characteristics of recurrent and non-recurrent ventricular tachyarrhythmias.
Group A Group B P-value
Shock therapy
(n¼8)
Non-shock therapy
(n¼20)
Age (years) 62.1719.8 64.3714.5 0.744
Male (n, %) 6 (75%) 14 (70%) 1.000
Underlying cardiac disease
Ischemic (n, %) 2 (25%) 11 (55%) 0.221
Non-ischemic (n, %) 6 (75%) 9 (45%) 0.221
BNP (pg/mL) 205.57270.9 164.47128.9 0.594
LVEF (%) 42.2712.5 48.0714.5 0.326
NYHA functional class 2.270.6 1.970.5 0.179
Medication
β Blockers (n, %) 8 (100%) 11 (55%) 0.029
ACE-inhibitors/ARBs (n, %) 7 (88%) 13 (65%) 0.371
Amiodarone 5 (62%) 6 (30%) 0.200
Electrocardiogram
Heart rate (bpm) 74.379.8 67.979.2 0.113
QRS duration (ms) 120.7725.7 114.5728.7 0.601
QTc interval (ms) 440.4722.1 449.8733.6 0.496
Holter monitoring
VPCs 2036.273018.9 610.371011.3 0.071
NSVT 5 (62%) 9 (45%) 0.678
Maximum TWA voltage
(μV)
79.8721.7 58.6719.1 0.018
TWA465 μV 7 (88%) 3 (15%) 0.004
SDNN (ms) 100.6731.7 113.6726.1 0.277
SDANN (ms) 86.8738.1 94.8721.6 0.494
TO (%) 0.2171.59 0.6272.04 0.621
TS (ms/RRI) 2.6673.11 7.0678.47 0.174
VPCs, ventricular premature complexes; NSVT, non-sustained ventricular tachycardia;
TWA, T-wave alternans; SDNN, standard deviation of all R–R intervals; SDANN,
standard deviation of the 5-min mean R–R intervals; TO, turbulence onset; and TS,
turbulence slope.
Table 3
Univariate Cox proportional hazard analysis of predictors of recurrent ventricular
tachyarrhythmias requiring shock therapy.
Odds ratio
(95% conﬁdence interval)
P-value
BNP (pg/mL) 1.002 (0.998–1.006) 0.367
LVEF (%) 0.975 (0.928–1.025) 0.327
Electrocardiogram
Heart rate (bpm) 1.068 (0.985–1.158) 0.113
QRS duration (ms) 1.007 (0.983–1.032) 0.585
QTc interval (ms) 0.992 (0.968–1.016) 0.510
Holter monitoring
NSVT 1.882 (0.448–7.907) 0.388
Maximum TWA values (μV) 1.026 (1.003–1.049) 0.028
TWA465 μV 13.17 (1.606–108.1) 0.016
SDNN (ms) 0.986 (0.960–1.012) 0.278
SDANN (ms) 0.990 (0.964–1.017) 0.483
TO (%) 1.084 (0.774–1.520) 0.639
TS (ms/RRI) 0.890 (0.732–1.082) 0.242
Abbreviations as in Table 2.
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speciﬁcity of TWA values (70.5 μV) in predicting recurrent ven-
tricular tachyarrhythmias were 87.5% and 90.0%, respectively.
For the conventionally proposed cutoff value of TWA (65 μV),
the sensitivity and speciﬁcity in the prediction of recurrent
ventricular tachyarrhythmias were 87.5% and 85.0%, respectively.
3.5. Association of T-wave alternans with recurrent ventricular
tachyarrhythmias
To evaluate the TWA voltage as a predictor for recurrent
ventricular tachyarrhythmias requiring shock therapy, the study
subjects were divided into two groups according to the TWA
voltage cutoff of 70.5 μV. Of the 28 patients, 9 (32%) had a TWA
voltage Z70.5 μV (high TWA group) and 19 (68%) had a voltage
o70.5 μV (low TWA group). During the follow-up period
(10.276.2 months), recurrent ventricular tachyarrhythmias
requiring appropriate shock therapy occurred more frequently in
the high TWA group than in the low TWA group (78% vs. 5%,
Po0.001), as shown in Fig. 3. Fig. 4 shows the overall event-free
probabilities for recurrent ventricular tachyarrhythmias according
to the TWA voltage. The Kaplan–Meier curves for recurrent
ventricular tachyarrhythmias differed signiﬁcantly between the
two groups (Po0.001). High TWA voltage was recognized as a
predictor for recurrent ventricular tachyarrhythmias requiring
shock therapy, compared with low TWA voltage.
4. Discussion
This is the ﬁrst study to show that TWA measured by the time-
domain modiﬁed moving average method is an effective predictor of
recurrent ventricular tachyarrhythmias requiring shock therapy in
survivors of VF or hemodynamically unstable VT. High values of
TWA were associated with recurrent ventricular tachyarrhythmias,
whereas other noninvasive parameters had no signiﬁcant association.
4.1. TWA and ventricular tachyarrhythmias after ICD implantation
TWA is considered to represent ventricular repolarization
abnormalities [17,18]. High TWA is known to be associated with
cardiac electrical instability, and TWA increases acutely prior to VT
or VF [19–21]. TWA is analyzed by the conventional power spectral
method using an exercise stress protocol, or by the time-domain
modiﬁed moving average method using Holter ECG recording. It is
sometimes impossible to perform TWA analysis by the power
spectral method, because treatment with β blockers or other
medications prevents the patients from increasing their heart rate
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Fig. 1. Comparison of T-wave alternans (TWA) values between Group A and Group
B. There were 7 (87.5%) patients with high TWA value (Z70.5 μV) in Group A and 2
(10.0%) in Group B.
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Fig. 2. Receiver-operating characteristic curve analysis for predicting recurrent
ventricular tachyarrhythmias. The optimal threshold value for T-wave alternans
(TWA) was 70.5 μV (sensitivity 87.5%, speciﬁcity 90.0%, and area under the curve
0.816).
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Fig. 3. Recurrence of ventricular tachyarrhythmias requiring shock therapy
between high T-wave alternans (TWA) voltage and low TWA voltage. Appropriate
shock therapy was delivered more frequently in the high TWA group than in the
low TWA group (78% vs. 5%, Po0.001).
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Fig. 4. The Kaplan–Meier analysis of T-wave alternans (TWA) in predicting the
recurrence of ventricular tachyarrhythmias (low TWA group: solid line vs. high
TWA group: dotted line). Event-free curves between the two groups differed
signiﬁcantly (Po0.001) by log-rank test.
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appropriately during exercise. On the other hand, TWA by the
time-domain method might be helpful in evaluating the risk of
recurrent ventricular tachyarrhythmias under treatment with β
blockers or other medications. Thus, in the present study we
investigated the risk for recurrent ventricular tachyarrhythmias
using TWA by the time-domain method.
Hoshida et al. reported that the average TWA voltage was
29720 μV in mildly depressed cardiac function judged by LVEF
(47711%), while TWA voltage 465 μV was associated with fatal
arrhythmic events [22]. In the patients of the present study, with
equivalently depressed cardiac function, the average TWA voltage
(64721 μV) was high compared to that in the study by Hoshida
et al. This may have been because our study subjects had the
arrhythmogenic substrate for ventricular tachyarrhythmias as a
result of their previous lethal ventricular tachyarrhythmias. In the
present study, ROC curve analysis for predicting recurrent ven-
tricular tachyarrhythmias indicated an optimal TWA value thresh-
old of 70.5 μV (sensitivity, 87.5%; speciﬁcity, 90.0%). Nieminen et al.
[10] reported that TWA voltage 465 μV was useful for predicting
fatal ventricular arrhythmias and sudden cardiac death in various
heart diseases. At the same time, they showed that the TWA cutoff
value of 65 μV had low sensitivity (35%) and high speciﬁcity (92%)
for predicting sudden cardiac death. However, A TWA cutoff value
of 65 μV in our study had both high sensitivity (87.5%) and high
speciﬁcity (85.0%) for predicting recurrent ventricular tachyar-
rhythmias. Thus, a TWA threshold modiﬁcation based on patient
background may provide more accurate identiﬁcation of patients
who are likely to suffer lethal ventricular tachyarrhythmias.
4.2. Other noninvasive parameters and ventricular tachyarrhythmias
after ICD implantation
Other than the measurement of TWA, previous studies
[9,15,23–26] have reported some predictors for the prevalence of
ventricular tachyarrhythmias, such as prolonged QRS duration and
QTc interval [24], the impairment of autonomic nervous control
[15,25], and left ventricular dysfunction [26]. There is ample
evidence for predicting sudden cardiac death in patients with
ischemic heart disease [15,23,25] or left ventricular systolic
dysfunction [23,27,28]. At present, however, little is known about
the predictive value of these markers in patients with non-
ischemic heart disease [27,29,30]. In the present study, with the
exception of TWA, noninvasive parameters were not identiﬁed as
predictors for recurrent ventricular tachyarrhythmias requiring
shock therapy. Possible considerations to be taken into account
regarding our results were that the cardiac function of our study
subjects judged by LVEF was mildly depressed, and that 15 (54%)
subjects were patients with non-ischemic heart disease.
4.3. Clinical implications
If a high value of TWA is related to recurrent ventricular
tachyarrhythmias requiring shock therapy, TWA-guided therapy
might be effective in reducing the prevalence of ventricular
tachyarrhythmias in the clinical setting. TWA abnormality can be
improved by treatment with β blockers [31]. Hreybe et al. [32]
reported that β blockers increased the 1-year shock-free survival
from 65% to 79% after ICD implantation for secondary prevention.
Despite medical treatment with β blockers in the present study, ICD
shock therapy was required and the maximum TWA voltage was
high. It might be difﬁcult to prevent the recurrence of ventricular
tachyarrhythmias requiring shock therapy using β blockers only.
Further investigation of improvements in ventricular repolarization
abnormalities could lead to the development of effective thera-
peutic strategies.
4.4. Limitations
Our study has some limitations. First, patients with atrial
ﬁbrillation were excluded, because the association between a high
value of TWA and atrial ﬁbrillation was uncertain. Atrial ﬁbrillation
is common in patients with depressed cardiac function [33], and
depressed cardiac function leads to a prevalence of ventricular
tachyarrhythmias [26]. It is necessary to clarify the relationship
between atrial ﬁbrillation and the risk of recurrent ventricular
tachyarrhythmias. Second, the present study was a retrospective
study; a prospective study will be needed in the future. Third, the
signal-averaged electrocardiogram and baroreceptor sensitivity
are also important for prediction of sudden cardiac death [9].
However, we did not examine the signal-averaged electrocardio-
gram and baroreceptor sensitivity for all the patients in the
present study. To improve patients' survival after ICD implanta-
tion, we should conduct additional research that includes these
markers.
5. Conclusion
The measurement of TWA by Holter monitoring is useful for
predicting recurrent ventricular tachyarrhythmias requiring shock
therapy in survivors of VF or hemodynamically unstable VT. The
maximum TWA voltage is high in patients who have survived VT
or VF. Thus, a modiﬁcation of the TWA threshold based on patient
background may provide more accurate identiﬁcation of patients
likely to suffer fatal ventricular tachyarrhythmias.
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